

Healthcare Industry Report

Q2 2025





Dinan is a premier global investment bank, with proficiency in mergers and acquisitions, capital markets, financial restructuring, and financial and valuation advisory.

We are the trusted advisor to hundreds of middle-market partners.

Contact Us

Please reach out to us to schedule a call to discuss this quarter's market update or to explore how we can serve your business needs.

[Request a meeting](#)

Leadership



Mike Dinan

President & CEO
mdinan@dinancapital.com
(602) 248-8700



Michael Brill

Managing Director
Head of Private Capital Markets
mbrill@dinancapital.com
(332) 266-3863



William Downing

Managing Director
wdowning@dinancapital.com
(602) 248-8700



Tom Gerlacher

Managing Director
tgerlacher@dinancapital.com
(312) 350-3966



Lisa Kaufman

Managing Director
lkaufman@dinancapital.com
(312) 953-9143



Rob Ullman

Managing Director
rullman@dinancapital.com
(650) 683-8181

About Dinan

Dinan & Company was founded with the singular purpose of providing the highest standards of professionalism, sophistication, and execution expertise in merger and acquisition and capital raising transactions for middle market companies comparable to that afforded to the Fortune 500 at full-service Wall Street investment banks.

The Dinan brand, representing both Dinan & Company and its subsidiary, Dinan Capital Advisors, unites deep institutional knowledge and collaborative resources to deliver a tailored, client-focused experience.

Creating \$70B+ in value through 900+ transactions closed since 1988, we would like to say thank you for your trust along the way.

Sector Coverage

Understanding a client's industry, growth opportunities, value drivers, and challenges is paramount to obtaining a successful engagement outcome. We provide our clients with senior-level industry expertise through our dedicated industry groups in the following sectors:

Building Products & Services

- Subcontractors

Business Services

- Financial Services
- Professional Services

Consumer

- B2C Services
- Consumer Products
- Food & Beverage

Healthcare

- Healthcare Products
- Physician Practice Management
- Post-Acute Care
- Provider & Payor Services

Industrials

- Aerospace & Defense
- Distribution
- Energy & Infrastructure
- Industrial Services
- Manufacturing

Technology

- IT & Managed Services
- Software
- Tech-enabled Services

Transportation & Logistics

Our clients benefit from
our local presence and global reach.



AMERICAS

Atlanta
Chicago
Nashville
New York City
Phoenix
San Francisco

EUROPE AND MIDDLE EAST

Amsterdam
Antwerp
Brussels
Copenhagen
Helsinki
London
Madrid

Manchester
Milan
Munich
Paris
Stockholm
Berlin
Zurich

ASIA- PACIFIC

Beijing
New Delhi
Singapore
Sydney
Tokyo

Fully Integrated Mergers and Acquisitions Specialists

30+

Senior officers dedicated to
financial advisory services globally

900+

Successful transactions⁽¹⁾

\$70B+

Total transaction value⁽¹⁾

300+


M&A professionals globally⁽²⁾

⁽¹⁾ Buy-side and Sell-side figure

⁽²⁾ Includes Translink, Dinan's exclusive international transaction partner


Percent Change of Healthcare Hires vs. Job Openings¹

In Q2 of 2025, the rate of change for healthcare job openings and hires moved in near lockstep, both rising 5–7% signaling a continuing trend of critical healthcare worker shortages.




Real vs. Nominal Healthcare PCE¹

In Q2 2025, the gap between nominal and real healthcare PCE continued to widen, underscoring that inflation, not increased utilization, is driving spending growth. This growing disconnect highlights price pressures and signals increased consumer spending without realizing increased care.




United States Healthcare AI Market³

The U.S. Healthcare AI market is projected to exceed \$110 billion by 2030, driven by the growing adoption of AI-powered diagnostics, personalized medicine, R&D, and predictive analytics.




Outsourced Pharma Development: CDMO Market Size²

The U.S. CDMO market grew from \$74 billion in 2023 to \$87 billion in 2024, reflecting a sustained shift toward outsourced development as pharmaceutical companies increasingly turn to external sources to accelerate R&D, manage costs, and scale production more efficiently.



Industry EV/EBITDA Multiples



Key Takeaways

Healthcare EBITDA multiples showed signs of recovery in Q2 2025, led by IT & Digital Health and Medical Devices & Equipment, while Managed Healthcare & Insurance showcased a softening in multiples.

21.4x

IT & Digital Health EBITDA Multiple (as of 06/30/2025)

18.5x

Medical Devices EBITDA Multiple (as of 6/30/2025)

Market Dynamics and Outlook


- The IT & Digital Health segment saw the strongest growth in Q2. As adoption of AI increased, particularly in diagnostics and patient engagement platforms, investors favored later-stage companies with proven applications.¹
- The Biotechnology sector saw an inflow of capital particularly toward oncology, rare disease, and immune targeted therapies, indicating that investors are prioritizing segments with higher pricing power and smaller patient populations.²
- The Pharmaceuticals sector Q2 performance was driven by continued strength in drug launches and late-stage trial execution. Drugmakers leaned more heavily on AI to streamline go-to-market.
- The Healthcare Services sector continued to face labor shortage and cost inflation, but adoption of flexible staffing and tech-enabled scheduling helped ease pressures.¹
- The Managed Healthcare & Insurance sector leveraged digital engagement tools and risk-sharing models to improve margins amid a stabilizing reimbursement landscape.
- The Medical Devices & Equipment sector saw stable procedural volume and rising demand for AI-powered imaging and robotic systems despite macro headwinds.
- The Life Sciences Tools & Services sector advanced in Q2 with continued AI investment, supporting the rising need for precision-driven drug discovery solutions.³

Dinan's Relevant Transactions

SignatureCare EMERGENCY CENTER Houston, TX has sold its Free-Standing Emergency Department in Paris, Texas to Lifepoint Health a portfolio company of APOLLO Atlanta, GA Dinan Capital Advisors acted as the exclusive financial advisor to SignatureCare Emergency Center in this transaction.	Team Select Phoenix, AZ received a strategic capital investment from SQUARE New York, NY Dinan Capital Advisors acted as financial co-advisor to Team Select Home Care in this transaction.	SignatureCare EMERGENCY CENTER Houston, TX has sold its network of eleven Free-Standing Emergency Departments ("FSEDs") in the Greater Houston area to HCA Healthcare Nashville, TN Dinan Capital Advisors acted as the exclusive financial advisor to SignatureCare Emergency Center in this transaction.	Team Select Phoenix, AZ has been acquired by TENEX New York, NY Dinan Capital Advisors acted as exclusive financial advisor to Team Select Holdings, LLC in this transaction.
DESERT SPINE and Sports Physicians Phoenix, AZ has received a strategic growth investment from NEW HARBOR Chicago, IL Dinan Capital Advisors acted as exclusive financial advisor to Desert Spine and Sports Physicians in this transaction.	IRN HOME CARE Colorado's Home Care Since 1985 Denver, CO has been acquired by Webster Eden Prairie, MN a portfolio company of Webster Eden Prairie, MN Dinan Capital Advisors acted as the exclusive financial advisor to IRN Home Care in this transaction.	DERM ONE Dermatology Care Bluefield, VA has been acquired by INTEGRATED DERMATOLOGY Boca Raton, FL Dinan Capital Advisors acted as exclusive financial advisor to Derm One in this transaction.	PHEN LECT (The Professional Companies) Phoenix, AZ has been acquired by Serent San Francisco, CA Dinan Capital Advisors acted as exclusive financial advisor to The Professional Companies in this transaction.

Sources: Capital IQ as of 6/30/2025, American Hospital Association¹, Investopedia², Grand View Research³
Note: Tombstones included herein represent transactions closed from 2020 forward

Market Cap Growth Rate



Key Takeaways

The Healthcare sector showed signs of recovery from the Q1 2025 downturn, led by a 20% equity return in the IT & Digital Health segment.

Managed Healthcare & Insurance continued to show signs of weakness, with a -27% decline in Q2 2025.

+20%

IT & Digital Health Equity Return (QoQ)

+11%

Healthcare Services Equity Return (QoQ)


Market Performance by Sector




% Equity Return

QoQ	-5.2%	QoQ	+11.2%	QoQ	-7.9%	QoQ	-27.3%	QoQ	-10.4%	QoQ	+0.9%	QoQ	+20.0%
YoY	-18.4%	YoY	+18.3%	YoY	-5.0%	YoY	-29.6%	YoY	-19.8%	YoY	+12.9%	YoY	+69.7%

Stock Price Performance - Dinan Healthcare Index vs. S&P 500



EBITDA Multiple Trends – Dinan Healthcare Index vs. S&P 500



Key Market Trends

Dinan Healthcare Index decreased -6% in Q2 2025, following a +4% increase in Q1 2025.

S&P 500 increased +11% in Q2 2025, following a -7% decrease in Q1 2025.

+14%

S&P 500 Equity
Return (YoY)

-11%

Healthcare Index
Equity Return (YoY)

Impact on Multiples

Dinan Healthcare Index EBITDA multiple decreased -10% in Q2 2025, following a +4% increase in Q1 2025.

S&P 500 EBITDA multiple increased +9% in Q2 2025, following a -7% decrease in Q1 2025.


+5%

S&P 500 Multiple
(YoY)


-16%

Healthcare Index
Multiple (YoY)

The S&P 500 rose 11% in Q2 '25 to record levels, reflecting a broader market recovery from volatility early in the year.



The 10-Year Treasury remained steady in the second quarter while consumer sentiment continued to decline.



U.S. Equity Sectors Performance

	% Return (Q1 '25)	% Return (Q2 '25)	TEV/LTM Total Rev	TEV/LTM EBITDA
Energy	+9.5%	-9.4%	1.6x	8.0x
Communication Services	-8.2%	+18.2%	4.9x	14.4x
Materials	+0.2%	+13.0%	2.7x	13.1x
Consumer Discretionary	-16.0%	+11.3%	3.2x	19.5x
Industrials	-2.3%	+12.6%	3.3x	19.1x
Info Tech	-14.7%	+23.5%	9.5x	27.8x
Healthcare	+6.1%	-7.6%	1.7x	14.3x
Consumer Staples	+1.8%	+0.5%	1.8x	16.2x
Real Estate	+2.1%	-1.0%	9.1x	20.9x
Utilities	+2.5%	+3.5%	5.0x	13.2x

Major Indices Performance

	% Return (Q1 '25)	% Return (Q2 '25)	TEV/LTM Total Rev	TEV/LTM EBITDA
S&P 500	-6.5%	+10.6%	3.6x	17.7x
NASDAQ	-12.2%	+16.7%	5.1x	21.1x
Dow Jones	-3.3%	+5.0%	3.2x	16.2x
Russell 2000	-9.9%	+8.1%	1.6x	12.6x

Interest Rates as of

	12/31/22	12/31/23	12/31/24	6/30/25
Treasury – 2 Year	4.4%	4.2%	4.3%	3.7%
Treasury – 5 Year	4.0%	3.8%	4.5%	3.8%
Treasury – 10 Year	3.9%	3.9%	4.6%	4.2%
Treasury – 30 Year	4.0%	4.0%	4.8%	4.8%
Prime Rate	7.5%	8.5%	7.5%	7.5%

Sources: Capital IQ as of 6/30/2025, FRED

(1) Rebased to 100 as of 1/3/2023

M&A activity in the Healthcare sector remained strong in Q2 2025, driven by strategic consolidation initiatives within the segment.

Closed Date	Target	Acquirer	Target Sector	Transaction Value (\$M)
6/3/2025	 FLORIDA CANCER SPECIALISTS & Research Institute	 MCKESSON	Healthcare Services	\$2,490
5/30/2025	 Checkpoint Therapeutics	 SUN PHARMA	Biotechnology	\$410
5/29/2025	 bluebird bio	 CARLYLE	Biotechnology	\$315
5/21/2025	 optinose®	 PARATEK	Pharmaceuticals	\$374
5/21/2025	 ACELYRIN	 alumis	Biotechnology	\$258
5/20/2025	 BIOLIFE®	 MERIT MEDICAL	Medical Devices	\$120
5/13/2025	 2seventybio	 Bristol Myers Squibb	Biotechnology	\$436
4/23/2025	 CRInstitute	 Roper TECHNOLOGIES	IT & Digital Health	\$1,850
4/21/2025	 Paragon	 ZIMMER BIOMET	Medical Devices	\$1,350
4/17/2025	 PATTERSON COMPANIES, INC.	 PATIENT SQUARE CAPITAL	Medical Devices	\$3,642
4/3/2025	 ANTHOS	 NOVARTIS	Biotechnology	\$3,100
4/2/2025	 Intra-Cellular THERAPIES	 Johnson & Johnson	Pharmaceuticals	\$14,654


Key Takeaways

M&A transaction volume in the Healthcare market lightened from Q1 2025 with activity remaining strong in the Healthcare Services and Pharmaceutical sectors.

Activity in the Healthcare Services and Pharmaceutical sectors was driven by regional consolidation of healthcare service systems and pharmaceutical pipeline diversification.

Overall Healthcare transaction volume has slowed from unsustainable pandemic driven volumes towards a more measured pace driven by strategic divestitures and continued consolidations.

M&A Transaction Volumes



Sources: Capital IQ as of 6/30/2025

Note: Chart represents both strategic and financial buyers



Network of Free-Standing Emergency Departments

- SignatureCare is a leading, Joint Commission Certified, operator of 24-Hour FSEDs in Texas, providing state-of-the-art facilities for delivering high-quality emergency medical care in the communities it serves.
- The process yielded an attractive strategic buyer in HCA Healthcare, a leading healthcare services provider in the United States, known for its extensive network of hospitals, urgent care centers, and physician clinics.

Key Positioning and Strategic Rationale

- Seeking to exit the Houston market, SignatureCare approached Dinan Capital Advisors to structure an outright sale of the company's eleven FSEDs in the geography.



Specialized Provider of Interventional Spine and Musculoskeletal Medicine

- Desert Spine and Sports Physicians is an industry-leading provider of non-surgical, interventional spine and musculoskeletal medicine, and non-opiate pain management.
- The endeavor identified an optimal purchaser in New Harbor Capital Management, a private equity firm renowned for its deep expertise in financing growth-driven healthcare services enterprises.

Key Positioning and Strategic Rationale

- Aiming to leverage expansion, Desert Spine consulted Dinan Capital Advisors to examine strategic options, ranging from a complete sale to a majority recapitalization.



Dedicated Specialty Home Healthcare Service Provider

- Team Select is a specialty home healthcare provider based in Phoenix, Arizona, supported by a proprietary data and technology platform across core post-acute service lines.
- The process yielded an ideal buyer in Court Square Capital Management, a private equity firm with substantial experience investing in growth-oriented healthcare services and technology businesses.

Key Positioning and Strategic Rationale

- Seeking to capitalize on recent growth and success, Team Select engaged Cantor Fitzgerald and Dinan Capital Advisors to explore strategic options in the market, leveraging Dinan's experience advising the founder on his first transaction in 2017.

Representative M&A Experience

 has acquired  Dinan & Company Initiated this transaction	 a portfolio company of  has partnered with  Dinan & Company Initiated this transaction	 a portfolio company of  has acquired  Dinan & Company Initiated this transaction	 a portfolio company of  has acquired  Dinan & Company Initiated this transaction	 has been acquired by  Dinan Capital Advisors acted as the exclusive financial advisor to IRN Home Care in this transaction	 has acquired  Dinan Capital Advisors acted as the exclusive financial advisor to SignatureCare Emergency Center in this transaction	 has acquired James S. Lewis, MD Chula Park, PA Dinan & Company Initiated this transaction	 a portfolio company of  has partnered with  Dinan & Company Initiated this transaction	 has sold its network of seven free-standing Emergency Departments ("SEDs") in the Greater Houston area to  Dinan Capital Advisors acted as the exclusive financial advisor to SignatureCare Emergency Center in this transaction	 has completed a business combination with  Fort Myers, FL Dinan & Company Initiated this transaction
 has partnered with  Dinan & Company Initiated this transaction	 has acquired  Dinan & Company Initiated this transaction	 a portfolio company of  has acquired  Dinan & Company Initiated this transaction	 received a strategic capital investment from  Dinan Capital Advisors acted as financial co-advisor to Team Select Home Care in this transaction	 a portfolio company of  has acquired  Dinan & Company Initiated this transaction	 a portfolio company of  has partnered with  Dinan & Company Initiated this transaction	 has received a strategic growth investment from  Dinan Capital Advisors acted as exclusive financial advisor to Desert Spine and Sports Physicians in this transaction	 has partnered with  a portfolio company of  Dinan Capital Advisors acted as exclusive financial advisor to Therapeutic Pathways in this transaction	 a portfolio company of  has partnered with  Dinan & Company Initiated this transaction	 has made an investment in  Danville, FL Dinan & Company Initiated this transaction
 has acquired  Dinan & Company Initiated this transaction	 has acquired  Dinan & Company Initiated this transaction	 has partnered with  Dinan & Company Initiated this transaction	 a portfolio company of  has acquired  Dinan & Company Initiated this transaction	 a portfolio company of  has partnered with  Dinan & Company Initiated this transaction	 a portfolio company of  has partnered with  Dinan & Company Initiated this transaction	 a portfolio company of  has acquired  Dinan & Company Initiated this transaction	 a portfolio company of  has acquired  Dinan & Company Initiated this transaction	 a portfolio company of  has acquired  Dinan & Company Initiated this transaction	 a portfolio company of  has acquired the revenue cycle management agreements of  Dinan & Company Initiated this transaction
 through their portfolio company  has acquired  Dinan & Company Initiated this transaction	 has been acquired by  Dinan Capital Advisors acted as exclusive financial advisor to DERM ONE in this transaction	 has partnered with  Dinan Capital Advisors acted as exclusive financial advisor to Branford Partners in this transaction	 has acquired  Dinan & Company Initiated this transaction	 has acquired  Dinan & Company Initiated this transaction	 has acquired  Dinan & Company Initiated this transaction	 through their portfolio company  has acquired  Dinan & Company Initiated this transaction	 a portfolio company of  has acquired  Dinan & Company Initiated this transaction	 a portfolio company of  has acquired  Dinan & Company Initiated this transaction	 has partnered with  Dinan & Company Initiated this transaction

Index Segmentation

Q2 2025



(\$ in millions, except per share data)

Ticker	Company Name	Stock Price	52 - Week		% of 52 Week High	Market Cap (\$ mm)	Enterprise Value (\$ mm)	Enterprise Value		TTM P/E
			High	Low				TTM Revenue	TTM EBITDA	
LSE:AZN	AstraZeneca PLC	\$138.6	\$183.4	\$131.2	75.6%	\$214,997.4	\$243,006.9	4.4x	13.3x	26.3x
NYSE:BMJ	Bristol-Myers Squibb Company	\$46.3	\$63.3	\$39.4	73.1%	\$94,203.9	\$133,407.9	2.8x	7.0x	17.3x
NYSE:LLY	Eli Lilly and Company	\$779.5	\$972.5	\$677.1	80.2%	\$699,811.9	\$734,814.7	15.0x	NM	63.4x
LSE:GSK	GSK plc	\$19.0	\$23.0	\$17.0	82.8%	\$77,052.4	\$95,471.3	2.3x	8.5x	18.3x
NYSE:JNJ	Johnson & Johnson	\$152.8	\$170.0	\$140.7	89.9%	\$367,527.7	\$380,998.7	4.3x	12.7x	17.0x
NYSE:MRK	Merck & Co., Inc.	\$79.2	\$129.9	\$73.3	60.9%	\$198,773.2	\$224,454.2	3.5x	7.8x	11.5x
SWX:NOVN	Novartis AG	\$120.9	\$129.2	\$102.0	93.6%	\$236,924.7	\$263,840.6	5.1x	11.9x	17.1x
CPSE:NOVO B	Novo Nordisk A/S	\$69.2	\$160.2	\$59.8	43.2%	\$307,213.5	\$319,362.9	7.3x	14.2x	18.7x
NYSE:PFE	Pfizer Inc.	\$24.2	\$31.5	\$20.9	76.9%	\$137,813.3	\$183,190.3	2.9x	7.9x	17.6x
ENXTPA:SAN	Sanofi	\$96.5	\$130.2	\$95.7	74.1%	\$117,616.3	\$130,190.6	2.9x	9.9x	16.5x
NYSE:TEVA	Teva Pharmaceutical Industries	\$16.8	\$22.8	\$12.5	73.5%	\$19,223.0	\$34,472.0	2.1x	7.7x	NM
Mean								4.8x	10.1x	22.4x
Median								3.5x	9.2x	17.4x

(\$ in millions, except per share data)										
Ticker	Company Name	Stock Price	52 - Week		% of 52 Week High	Market Cap (\$ mm)	Enterprise Value (\$ mm)	Enterprise Value		TTM P/E
			High	Low				TTM Revenue	TTM EBITDA	
NasdaqGS:ADUS	Addus HomeCare Corporation	\$115.2	\$136.7	\$89.0	84.3%	\$2,091.3	\$2,245.1	1.9x	16.0x	26.1x
NasdaqGS:AMED	Amedisys, Inc.	\$98.4	\$99.0	\$82.2	99.4%	\$3,229.1	\$3,441.7	1.5x	14.1x	36.2x
NYSE:CYH	Community Health Systems, Inc.	\$3.4	\$6.3	\$2.2	54.1%	\$454.7	\$12,596.7	1.0x	10.1x	NM
NYSE:DVA	DaVita Inc.	\$142.5	\$179.6	\$131.8	79.3%	\$10,755.0	\$24,490.4	2.0x	9.2x	14.1x
NYSE:EHC	Encompass Health Corporation	\$122.6	\$123.1	\$82.7	99.6%	\$12,360.7	\$15,746.2	2.9x	12.8x	25.2x
NYSE:HCA	HCA Healthcare, Inc.	\$383.1	\$417.1	\$290.0	91.8%	\$92,163.9	\$140,513.9	2.0x	9.9x	17.0x
NYSE:LH	Labcorp Holdings Inc.	\$262.5	\$264.0	\$199.0	99.4%	\$21,972.1	\$28,201.6	2.1x	16.4x	30.3x
NYSE:DGX	Quest Diagnostics Incorporated	\$179.6	\$182.4	\$136.3	98.5%	\$20,053.1	\$26,555.1	2.6x	13.4x	22.7x
NYSE:SEM	Select Medical Holdings Corporation	\$15.2	\$41.0	\$14.0	37.0%	\$1,951.2	\$5,011.7	1.0x	13.0x	31.3x
NYSE:THC	Tenet Healthcare Corporation	\$176.0	\$177.3	\$109.8	99.3%	\$16,347.8	\$30,990.8	1.5x	7.4x	11.7x
NYSE:UHS	Universal Health Services, Inc.	\$181.2	\$243.3	\$154.0	74.5%	\$11,673.4	\$16,740.9	1.0x	7.1x	10.2x
Mean								1.8x	11.8x	22.5x
Median								1.9x	12.8x	24.0x

(\$ in millions, except per share data)										
Ticker	Company Name	Stock Price	52 - Week		% of 52 Week High	Market Cap (\$ mm)	Enterprise Value (\$ mm)	Enterprise Value		TTM P/E
			High	Low				TTM Revenue	TTM EBITDA	
NYSE:ABBV	AbbVie Inc.	\$185.6	\$218.7	\$163.5	84.9%	\$327,879.7	\$392,769.7	6.8x	14.4x	79.3x
NasdaqGS:AMGN	Amgen Inc.	\$279.2	\$346.9	\$253.3	80.5%	\$150,132.9	\$198,703.9	6.1x	12.6x	25.5x
NasdaqGS:BIB	Biogen Inc.	\$125.6	\$238.0	\$110.0	52.8%	\$18,402.4	\$22,425.3	2.3x	7.3x	12.4x
NasdaqGS:BNTX	BioNTech SE	\$106.5	\$131.5	\$76.5	81.0%	\$26,216.7	\$11,282.9	3.8x	NM	NM
NasdaqGS:GILD	Gilead Sciences, Inc.	\$110.9	\$120.0	\$66.0	92.4%	\$137,914.4	\$154,071.4	5.4x	11.2x	23.4x
NasdaqGS:INCY	Incyte Corporation	\$68.1	\$84.0	\$53.6	81.1%	\$13,182.1	\$10,816.6	2.5x	NM	NM
NasdaqGS:MRNA	Moderna, Inc.	\$27.6	\$129.4	\$23.2	21.3%	\$10,670.2	\$3,022.2	1.0x	NM	NM
NasdaqGS:REGN	Regeneron Pharmaceuticals, Inc.	\$525.0	\$1,211.2	\$476.5	43.3%	\$55,474.4	\$40,553.5	3.0x	9.1x	13.3x
NasdaqGS:VRTX	Vertex Pharmaceuticals Incorporated	\$445.2	\$519.9	\$377.9	85.6%	\$114,326.1	\$104,617.5	9.4x	22.8x	NM
Mean								4.5x	12.9x	30.8x
Median								3.8x	11.9x	23.4x

(\$ in millions, except per share data)										
Ticker	Company Name	Stock Price	52 - Week		% of 52 Week High	Market Cap (\$ mm)	Enterprise Value (\$ mm)	Enterprise Value		TTM P/E
			High	Low				TTM Revenue	TTM EBITDA	
NYSE:CNC	Centene Corporation	\$54.3	\$80.6	\$52.9	67.4%	\$27,009.9	\$30,617.9	0.2x	4.7x	8.1x
NYSE:CVS	CVS Health Corporation	\$69.0	\$72.5	\$43.6	95.1%	\$87,261.0	\$156,001.0	0.4x	11.2x	16.5x
NYSE:ELV	Elevance Health, Inc.	\$389.0	\$567.3	\$357.5	68.6%	\$87,879.5	\$110,499.5	0.7x	11.2x	15.2x
NYSE:HUM	Humana Inc.	\$244.5	\$406.5	\$212.5	60.1%	\$29,507.1	\$39,059.1	0.3x	9.5x	17.3x
NYSE:MOH	Molina Healthcare, Inc.	\$297.9	\$365.2	\$262.3	81.6%	\$16,146.2	\$15,056.2	0.4x	8.2x	14.4x
NYSE:UNH	UnitedHealth Group Incorporated	\$312.0	\$630.7	\$248.9	49.5%	\$283,000.6	\$343,685.6	0.9x	9.5x	13.1x
Mean								0.5x	9.1x	14.1x
Median								0.4x	9.5x	14.8x

(\$ in millions, except per share data)										
Ticker	Company Name	Stock Price	52 - Week		% of 52 Week High	Market Cap (\$ mm)	Enterprise Value (\$ mm)	Enterprise Value		TTM P/E
			High	Low				TTM Revenue	TTM EBITDA	
NYSE:A	Agilent Technologies, Inc.	\$118.0	\$153.8	\$96.4	76.7%	\$33,522.5	\$35,720.5	5.4x	19.5x	29.1x
NasdaqGS:ICLR	ICON Public Limited Company	\$145.5	\$347.7	\$125.1	41.8%	\$11,558.1	\$14,626.3	1.8x	9.0x	15.8x
NasdaqGS:ILMN	Illumina, Inc.	\$95.4	\$156.7	\$68.7	60.9%	\$15,103.4	\$16,473.4	3.8x	17.2x	NM
NYSE:IQV	IQVIA Holdings Inc.	\$157.6	\$252.9	\$134.6	62.3%	\$27,263.1	\$39,933.1	2.6x	13.6x	21.5x
SWX:LONN	Lonza Group AG	\$710.4	\$774.6	\$588.2	91.7%	\$50,183.1	\$54,680.9	7.5x	NM	63.3x
NYSE:TMO	Thermo Fisher Scientific Inc.	\$405.5	\$627.9	\$385.5	64.6%	\$153,058.7	\$181,465.7	4.2x	16.8x	23.8x
Mean								4.2x	15.2x	30.7x
Median								4.0x	16.8x	23.8x

(\$ in millions, except per share data)										
Ticker	Company Name	Stock Price	52 - Week		% of 52 Week High	Market Cap (\$ mm)	Enterprise Value (\$ mm)	Enterprise Value		TTM P/E
			High	Low				TTM Revenue	TTM EBITDA	
NYSE:ABT	Abbott Laboratories	\$136.0	\$141.2	\$99.7	96.3%	\$236,635.2	\$243,334.2	5.7x	22.1x	17.7x
NYSE:BDX	Becton, Dickinson and Company	\$172.3	\$252.0	\$163.3	68.4%	\$49,368.1	\$67,955.1	3.3x	12.2x	33.4x
NYSE:BSX	Boston Scientific Corporation	\$107.4	\$107.5	\$71.9	99.9%	\$158,907.3	\$170,123.3	9.7x	NM	78.4x
NasdaqGS:XRAY	DENTSPLY SIRONA Inc.	\$15.9	\$28.0	\$12.2	56.8%	\$3,164.8	\$5,206.8	1.4x	8.9x	NM
NasdaqGS:GEHC	GE HealthCare Technologies Inc.	\$74.1	\$94.8	\$57.7	78.1%	\$33,915.5	\$40,876.5	2.1x	11.2x	15.6x
NYSE:MDT	Medtronic plc	\$87.2	\$96.3	\$76.0	90.6%	\$111,687.8	\$132,563.8	4.0x	14.5x	24.1x
XTRA:SHL	Siemens Healthineers AG	\$55.3	\$68.7	\$48.4	80.5%	\$61,607.6	\$78,617.6	3.1x	17.8x	25.3x
NYSE:STE	STERIS plc	\$240.2	\$252.8	\$201.0	95.0%	\$23,630.7	\$25,673.9	4.7x	17.5x	39.0x
NYSE:SYK	Stryker Corporation	\$395.6	\$406.2	\$314.9	97.4%	\$151,195.9	\$166,142.9	7.2x	NM	53.5x
NYSE:TFX	Teleflex Incorporated	\$118.4	\$249.9	\$115.9	47.4%	\$5,230.2	\$6,965.0	2.3x	8.3x	37.0x
NasdaqGS:COO	The Cooper Companies, Inc.	\$71.2	\$112.4	\$65.0	63.3%	\$14,197.3	\$16,940.9	4.2x	15.1x	34.4x
NYSE:ZBH	Zimmer Biomet Holdings, Inc.	\$91.2	\$116.7	\$89.2	78.2%	\$18,045.7	\$23,995.3	3.1x	9.4x	20.2x
Mean								4.2x	13.7x	34.4x
Median								3.6x	13.4x	33.4x

(\$ in millions, except per share data)

Ticker	Company Name	Stock Price	52 - Week		% of 52 Week High	Market Cap (\$ mm)	Enterprise Value (\$ mm)	Enterprise Value		TTM P/E
			High	Low				TTM Revenue	TTM EBITDA	
NYSE:AMWL	American Well Corporation	\$8.9	\$13.0	\$5.0	68.6%	\$138.8	-\$64.5	NM	0.5x	NM
NYSE:DOCS	Doximity, Inc.	\$61.3	\$85.2	\$25.0	72.0%	\$11,521.3	\$10,618.0	18.6x	NM	55.3x
NYSE:EVH	Evolent Health, Inc.	\$11.3	\$33.6	\$7.1	33.5%	\$1,304.6	\$2,121.4	0.9x	25.1x	NM
NYSE:IBM	International Business Machines	\$294.8	\$296.2	\$173.4	99.5%	\$268,071.9	\$317,513.9	5.1x	22.8x	50.4x
NYSE:TDOC	Teladoc Health, Inc.	\$8.7	\$15.2	\$6.4	57.3%	\$1,528.0	\$1,921.5	0.8x	NM	NM
Mean								6.3x	16.1x	52.8x
Median								3.0x	22.8x	52.8x



Mergers & Acquisitions
Private Capital Markets
Valuations & Fairness Opinions
Merchant Banking

dinancapital.com